The use of mTOR inhibitors is associated with improved survival in lung transplant recipients

Y. Lebel-Shostak (Petah-Tikva, Israel), B. Pertzov (Petah-Tikva, Israel), O. Grossberger (Petah-Tikva, Israel), D. Rosengarten (Petah-Tikva, Israel), D. Shitenberg (Petah-Tikva, Israel), M. Heshing (Petah-Tikva, Israel), S. Amor (Petah-Tikva, Israel), M. Kramer (Petah-Tikva, Israel)

Source: Virtual Congress 2020 – Treatments and biomarkers for lung allograft function and outcome
Session: Treatments and biomarkers for lung allograft function and outcome
Session type: Oral Presentation
Number: 4724
Disease area: Respiratory infections

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Y. Lebel-Shostak (Petah-Tikva, Israel), B. Pertzov (Petah-Tikva, Israel), O. Grossberger (Petah-Tikva, Israel), D. Rosengarten (Petah-Tikva, Israel), D. Shitenberg (Petah-Tikva, Israel), M. Heshing (Petah-Tikva, Israel), S. Amor (Petah-Tikva, Israel), M. Kramer (Petah-Tikva, Israel). The use of mTOR inhibitors is associated with improved survival in lung transplant recipients. 4724

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you: